Palo Alto – February 24, 2026 – Cooley advised Frontier Biotechnologies (Frontier Biotech), a research-based, commercial-stage, publicly traded biopharma company dedicated in the discovery, development, manufacture and commercialization of innovative medicines, on its exclusive licensing agreement with GSK, a global biopharma company.

Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of Frontier Biotech's small interfering RNA (siRNA) pipeline products, one of which is currently at the investigational new drug stage and the other a preclinical candidate.

Frontier Biotech will receive $40 million upfront and up to $963 million in success-based development, regulatory and commercial milestones in total across the two programs, as well as tiered royalties on net sales worldwide.

A life sciences partnering team of Lila Hope, Joe Sandys and Alexandra Paterson led the Cooley team advising Frontier Biotech, with valuable assistance from Jennifer Raab, and Eerik Kukebal, Jack Jones and David Wilson advising on tax matters.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.